Summary
Virtus Biotech Clinical Trials ETF is an ETF - a fund traded on an exchange like a stock - run by Virtus. Positions inside: 130. The ten largest make up 15% of the fund.
- Yearly costs
- 0.65%
- Fund size
- $39.2M
- Positions
- 130
- Dividend yield
- 1.56%
- Running since
- 2014
What speaks for it
- Widely spread: the ten largest positions make up only 15% of the fund.
- Average yearly growth over the last ten years: 7.8%.
- It has been running since 2014.
What to watch
- 100% of the fund is in one sector (Healthcare).
- 90% of the fund is in one country (United States).
- Costs of 0.65% a year are above the middle of comparable funds (0.44%).
- In the last five years its price once dropped by 77% from its high.
- A small fund with $39.2M under management; small funds get closed more often.
- It trades little: only about $982.0K changes hands a day.
A fund has no Bulios Score and no Fair Price of its own - both are computed from the results of a single company. This page shows what is inside the fund and what it costs instead.
Price
Performance
- 1 month
- -9.7%
- 3 months
- -16%
- This year
- +9.3%
- 1 year
- +40%
- 3 years
- +145%
- 5 years
- -4.9%
- 10 years
- +111%
- Avg. market cap
- $3.27B
- P/E
- -
- Forward P/E
- -
- P/S
- -
- P/B
- 4.1x
- P/FCF
- -
- EV/EBITDA
- -
- Dividend yield
- 0.00%
- ROIC
- -485.5%
- ROE
- -95.9%
- Gross margin
- -
- Operating margin
- -
- Net margin
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 1.34
Weighted average of the 50 largest companies, which make up 52% of the fund. Banks and insurers are left out of the gross margin, the ROIC and the EBITDA figures.
What is inside?
Widely spread- 1 KOKodiak Sciences Inc. KOD 2.1%
- 2 ABAbCellera Biologics Inc. ABCL 2.0%
- 3 TRFirst Tracks Biotherapeutics Inc TRAX 1.7%
- 4 XNXencor, Inc. XNCR 1.6%
- 5 AMAmylyx Pharmaceuticals, Inc. AMLX 1.5%
- 6 ORORIC Pharmaceuticals, Inc. ORIC 1.3%
- 7 NRNurix Therapeutics, Inc. NRIX 1.2%
- 8 FD4D Molecular Therapeutics, Inc. FDMT 1.2%
- 9 SLSELLAS Life Sciences Group, Inc. SLS 1.2%
- 10 MBMBX Biosciences, Inc. Common Stock MBX 1.2%
Positions in the fund: 130. The ten largest make up 15% of it.
Composition as of Oct 18, 2026.
Where is it spread?
One sector dominatesBy sector
- Healthcare 100%
By country
- United States 90%
- Canada 2.5%
- Netherlands 2.0%
- Ireland 1.6%
- Other countries 4.2%
By company size
- Large cap 1.9%
- Mid cap 33%
- Small cap 60%
- Micro cap 4.9%
By the company's market value: Mega cap from $200B, Large cap from $10B, Mid cap from $2B, Small cap from $300M, Micro cap below $300M.
Largest sector: Healthcare (100%). Largest country: United States (90%). Largest size group: Small cap (60%).
What does it cost me?
Expensive- A year from $10,000
- $65.00
- Over 20 years
- $3,099
From every $10,000 invested the fund takes $65.00 a year. You do not pay it separately - it is taken out of the fund's value. Over 20 years at 5% yearly growth that adds up to about $3,099.
How has it done?
Growing over the long run- A year on average, 10 years
- +7.8%
- Deepest drop
- -77%
- Yearly volatility
- 38%
Average yearly growth over the last ten years: 7.8%. Deepest drop in these years: 77% below the earlier high.
Does it pay dividends?
Yes, it pays out- Yield
- 1.56%
- Payments a year
- 1
- Last payment
- $0.66
Over the last 12 months it paid $0.66 per share, which is 1.56% of today's price. The last payment was $0.66 on Dec 22, 2025.
Is it easy to buy and sell?
It trades little- Traded a day
- $982.0K
- Shares a day
- 23K
On an average day about $982.0K of the fund changes hands.
How expensive are the companies inside?
Rather expensive- Average Bulios Score
- 38 out of 100
Weight by Bulios Fair Price
- Undervalued 3.0%
- Fairly valued 0.0%
- Overvalued 97%
By Fair Price, 97% of the rated weight comes out as overvalued.
Counted from its largest companies (50), which make up 52% of the fund. Each company counts by its weight. We use the metrics, the Bulios Score and the Fair Price of the companies themselves.
Similar funds
Funds that hold much of the same. The overlap says how much of their weight they share with this fund.
| Fund | Domicile | Size | 1-year change | Dividends | ||
|---|---|---|---|---|---|---|
SB SBIO ALPS Medical Breakthroughs ETF | United States | 0.50% | $172.9M | +30% | Pays out | 38% |
XB XBI SPDR S&P Biotech ETF | United States | 0.35% | $7.55B | +41% | Pays out | 32% |
TD TDNA T. Rowe Price Biotech ETF | United States | 0.55% | $9.09M | - | - | 32% |
CU CURE.AX Global X - S&P Biotech ETF | Australia | 0.45% | $27.4M | +32% | Reinvests | 32% |
FB FBIOX Fidelity Select Biotechnology Pt· mutual fund | United States | - | $5.81B | +22% | Pays out | 27% |
LA LABU Direxion Daily S&P Biotech Bull 3X Shares | United States | 0.96% | $1.06B | +100% | Pays out | 26% |
